Information  X 
Enter a valid email address

Tissue Regenix Group (TRX)

  Print   

Tuesday 26 April, 2022

Tissue Regenix Group

Result of AGM

RNS Number : 4217J
Tissue Regenix Group PLC
26 April 2022
 

Tissue Regenix Group plc

("Tissue Regenix" or "the Group")

 

Result of AGM

 

Tissue Regenix Group (AIM:TRX), the regenerative medical devices company, announces that at the AGM held earlier today, all resolutions were duly passed on a show of hands.

 

The results of the poxy are set out below:

 

Resolution

 

In favour

%

Against

%

Withheld

1

Ordinary

3,096,432,946

99.87

4,000,000

0.13

859,285

2

Ordinary

3,091,355,706

99.71

9,104,066

0.29

832,459

3

Ordinary

3,096,355,706

99.87

  4,104,066

0.13

832,459

4

Ordinary

3,091,355,706

99.71

9,104,066

0.29

832,459

5

Ordinary

3,091,355,706

99.71

9,104,066 

0.29

832,459

6

Ordinary

3,091,355,706

99.71

9,104,066

0.29

832,459

7

Ordinary

3,091,355,706

99.71

9,104,066

0.29

832,459

8

Ordinary

3,096,379,267

99.87

4,080,505

0.13

832,459

9

Ordinary

3,096,379,267

99.87

4,080,505

0.13

832,459

10

Ordinary

3,090,580,199

99.68

9,826,573

0.32

885,459

11

Special

3,059,344,373

98.68

41,062,399

1.32

885,459

12

Special

3,085,499,489

99.49

15,789,742

0.51

3,000

 

NB: Percentage of Votes case excludes Withheld votes

 

The full text of the resolutions passed at the AGM may be found in the Notice of AGM published on 15 March 2022

 

For more information:

 

Tissue Regenix Group plc

David Cocke, Chief Financial Officer

www.tissueregenix.com

Via Walbrook PR

 

 

Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)

Ben Maddison / Nick Harland

Tel:  +44(0)20 7710 7600 

Walbrook PR Ltd

Alice Woodings / Lianne Applegarth

Tel: +44 (0)20 7933 8780

[email protected]

 

 

About Tissue Regenix (www.tissuergenix.com)

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or damaged body structures. Current applications address many critical clinical needs such as in sports medicine, foot and ankle, and wound care.

 

In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, dental, and ophthalmological surgical procedures.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGSEMFIMEESEFL

a d v e r t i s e m e n t